Merck: Exploiting Erbitux
Executive Summary
Merck KGAA's fortunes are tied precariously to the industry's most controversial product, cancer drug Erbitux. Since it relies on Erbitux to fill the gap left by falling Glucophage revenues as well as to spearhead a wider move into oncology, Merck is trying to treat Erbitux's bumpy ride to date as an opportunity, not a threat.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?